MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Xenon Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

31.56 -1.71

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.43

Max

31.79

Pagrindiniai rodikliai

By Trading Economics

Pajamos

638K

-65M

Pardavimai

7.5M

7.5M

Pelno marža

-867.293

Darbuotojai

316

EBITDA

4.1M

-73M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+76.13% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-244M

2.5B

Ankstesnė atidarymo kaina

33.27

Ankstesnė uždarymo kaina

31.56

Naujienos nuotaikos

By Acuity

21%

79%

44 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-18 21:01; UTC

Uždarbis

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-07-18 20:46; UTC

Uždarbis

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

2025-07-18 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025-07-18 20:36; UTC

Uždarbis

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

2025-07-18 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

2025-07-18 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-18 20:02; UTC

Rinkos pokalbiai

Gold Higher to Close Out Week -- Market Talk

2025-07-18 19:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

2025-07-18 19:06; UTC

Rinkos pokalbiai

Oil Futures Snap Two-Week Winning Streak -- Market Talk

2025-07-18 18:24; UTC

Uždarbis

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

2025-07-18 18:19; UTC

Uždarbis

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

2025-07-18 18:11; UTC

Įsigijimai, susijungimai, perėmimai

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

2025-07-18 18:11; UTC

Uždarbis

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

2025-07-18 17:35; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

2025-07-18 16:29; UTC

Rinkos pokalbiai

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

2025-07-18 16:28; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025-07-18 16:22; UTC

Uždarbis

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-07-18 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-18 16:04; UTC

Uždarbis

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

2025-07-18 15:58; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-18 15:58; UTC

Rinkos pokalbiai

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

2025-07-18 15:47; UTC

Rinkos pokalbiai
Uždarbis

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Akcijų palyginimas

Kainos pokytis

Xenon Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

76.13% į viršų

12 mėnesių prognozė

Vidutinis 55.64 USD  76.13%

Aukščiausias 65 USD

Žemiausias 47 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Xenon Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

14

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

34.81 / 38.24Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

44 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.